Celgene Amends its Existing Collaboration with Editas to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for Cancer and Autoimmune Diseases

 Celgene Amends its Existing Collaboration with Editas to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for Cancer and Autoimmune Diseases

Celgene Collaborates with Exscientia for its AI Drug Discovery Platform

Shots:

  • Editas to receive $70M up front, milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in to such genome editing tools for the development of gene-edited alpha-beta T cell therapies
  • In May’2015, Editas and Juno entered into an exclusive collaboration to develop CAR T and TCR Cell Therapies, under which Editas has received $25M as upfront & ~$22M to support research over the next five years across the three programs in the alliance along with $230M research, regulatory, and commercial milestones and royalties for each program
  • The amended agreement replaces the original agreement, allowing Editas to develop non-alpha-beta T cell therapies while expanding Celgene’s access to gene-edited alpha-beta T cells beyond oncology

Click here to­ read full press release/ article | Ref: Editas  | Image: The Boston Globe

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post